Symbols

COCP

Cocrystal Pharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About COCP

Cocrystal Pharma, Inc.

A clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus

Industry

Pharmaceutical

Established Date

01/02/2014

Listing Date

03/12/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cocrystalpharma.com

Security Type

Common stock

Office address

19805 North Creek Parkway, Bothell, WA 98011

Business

Introduction

Cocrystal Pharma, Inc., was incorporated in Delaware on January 2, 2014. Its main business is the development of new drugs for the treatment of human viral diseases. Since investing in 2008, Cocrystal Pharma, Inc., has been committed to developing novel technologies and methods to create best-in-class antiviral drugs. The company's focus is on pursuing the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prevention of viral diseases in humans. The company plans to use their infrastructure and expertise in these areas to focus research and development efforts on viral replication inhibitors.

Company Financials

EPS

COCP has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.22, beating expectations. The chart below visualizes how COCP has performed over recent quarters, highlighting trends in earnings surprises.